Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth
8.7.2024 14:00:00 EEST | Business Wire | Press release
Bracco and Blue Earth Diagnostics Ltd, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of Marco Campione as its new Chief Executive Officer (CEO), reporting to Bracco Imaging CEO Fulvio Renoldi Bracco. Mr. Campione also joins the Blue Earth Diagnostics Ltd Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors. Dr. David Gauden, a co-founder of Blue Earth Diagnostics and with the Company since 2014, assumes the role of full-time CEO of Bracco subsidiary Blue Earth Therapeutics. The changes reflect a carefully planned strategy to drive continued growth, development and opportunity for both companies and Bracco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240708534807/en/
Marco Campione, Chief Executive Officer, Blue Earth Diagnostics, a Bracco company (Photo: Business Wire)
“I congratulate Marco Campione on this CEO appointment and we look forward to drawing upon his strategic, operational and broad general business expertise as we increase our global leadership throughout the diagnostic radiopharmaceutical industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. “Marco joins the Bracco Group at a transformative point in our evolution, as the company matures, broadens its horizons globally and expands its commercial presence.”
Mr. Renoldi continued, “I also want to take this opportunity to recognize the many contributions of David Gauden in advancing the success of Blue Earth Diagnostics, and I wish him the best of success in now leading Blue Earth Therapeutics as its full-time CEO.”
“I am excited and honored to assume the role of CEO at Blue Earth Diagnostics,” said Mr. Campione. “The Company is a recognized leader throughout the nuclear medicine and oncology communities, having a strong reputation grounded in successful innovation, execution and dedicated service on behalf of patient health. I look forward to applying my experience towards expanding availability of the Company’s PET imaging products for prostate cancer, advancing its development programs in PET neuro-oncology and solid tumors, and in exploring additional opportunities and collaborations.”
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc.
About Blue Earth Diagnostics
Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240708534807/en/
Contacts
For Blue Earth Diagnostics (U.S.)
Priscilla Harlan
Vice President, Corporate Communications
(M) (781) 799-7917
priscilla.harlan@blueearthdx.com
For Blue Earth Diagnostics (UK)
Clare Gidley
Associate Director Marketing and Communications
Tel: +44 (0)1865 784186
clare.gidley@blueearthdx.com
Media
Sam Brown Inc.
Mike Beyer
(M) (312) 961-2502
mikebeyer@sambrown.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 15:30:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, tolerability, and clinical effects of RLS-1496 1% cream in adult patients with AK on the forearms. RLS-1496 is the first selective glutathione peroxidase 4 (GPX4) modulator to be studied in human trials, and the first targeting cellular rejuvenation as a new therapeutic pathway in a novel category called Adaptive SenoTherapeutics. Interim data from the study were presented at the RBC Capital Markets Global Healthcare Conference in New York City on May 19, 2026. Preliminary RLS-1496 Actinic Keratosis Trial Results The Phase 1b/2a
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark the eighth consecutive year of wins for ExaGrid at the Networ
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 15:00:00 EEST | Press release
Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM to trace a five-step dependency chain across the real estate, and accuracy collapses. The answer arrives with confidence. The architect inherits the consequ
European DataWarehouse Launches DealDox ® , a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 15:00:00 EEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 14:47:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native environment. By enabling teams to work concurrently using shared data and standardized workflows, the approach reduces handoffs and rework and supports more consistent, timely decis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom